Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Emisphere Technologies, Inc. EMIS

Healthcare Drug Manufacturers - Major
"Emisphere Technologies Inc is a pharmaceutical and drug delivery company. It aims to partner its proprietary drug delivery technology and license its first medical food product Eligen B12, which is used to normalize vitamin B12 levels without an injection. The company is in partnership with global pharmaceutical companies to develop new oral formulations of existing injectable bio-pharmaceutical products, as well as new chemical entities, using its Eligen Technology. The company recognizes its


OTCPK:EMIS - Post by User

Emisphere Technologies, Inc.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by mhoganon Jan 30, 2000 6:50pm
197 Views
Post# 1297669

FYI

FYIIn the news, EMIS received a nice little blurb on January 20th in the Hambrecht and Quist 18th Annual Healthcare Conference Issue regarding the continuing success and broadening use of its Herapin products. The stock closed up $3.81 the following day. There is some conflicting information out there regarding the date of the next earnings announcement, but using history as our guide, we believe there should be one mid-March. We will be confirming the exact date with the company next week.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities